INDIANAPOLIS and ENCINO, Calif., Jan. 19, 2016 /PRNewswire/ -- PTS Diagnostics, Infopia Co., LTD, Infopia America LLC, and Jant Pharmacal Corporation today announced the settlement of PTS Diagnostics’ claims that Infopia’s HDL-cholesterol testing products sold by Jant in the United States infringe PTS Diagnostics’ U.S. patent no. 7,087,397. The settlement was entered into by the parties to amicably resolve pending litigation without admission of liability or lack of liability by any party.
In recognition of limited sales and the expenses associated with protracted patent litigation, the sale of LipidPlus test strips that contain the HDL-cholesterol test will be discontinued over a period of time in the United States. The sales of products that do not contain a current LipidPlus HDL-cholesterol test remain unaffected.
The settlement resolves PTS Diagnostics’ claims in both United States District Court and the International Trade Commission. In light of the terms of the settlement, Jant and Infopia have dropped all challenges to the validity and enforceability of PTS Diagnostics’ patent in perpetuity and PTS Diagnostics has released Infopia and Jant (and their customers) from all claims that could have been made relating to use of the LipidPlus products.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pts-diagnostics-and-jant-pharmacal-corporation-jointly-resolve-pending-litigation-300205968.html
SOURCE PTS Diagnostics; Jant Pharmacal Corporation
